Deterrents to the successful clinical use of growth factors that enhance protein anabolism

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 2, Issue 1, 1999, Pages 15-21

  Wilmore, Douglas W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; GROWTH PROMOTOR; PROTEIN;

CLINICAL TRIAL; DIET; HUMAN; METABOLISM; NUTRITIONAL STATUS; REVIEW; SPORTS MEDICINE; TREATMENT OUTCOME;

ANABOLIC AGENTS; CLINICAL TRIALS; DIET; GROWTH SUBSTANCES; HUMANS; NUTRITIONAL STATUS; PROTEINS; SPORTS MEDICINE; TREATMENT OUTCOME;

EID: 0032617633     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199901000-00004     Document Type: Article

References (45)

1. Wilmore DW. Catabolic illness, strategies for enhancing recovery. N Engl J Med 1991; 325:695-702.
2. Plank LD, Connolly AB, Hill GL. Sequential changes in metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann Surg 1998; 228:146-158. This study highlights the effect of peritonitis on protein catabolism.
3. Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma 1987; 27:262-264.
4. Wamold I, Eden E, Lundholm K. The inefficiency of total parenteral nutrition to stimulate protein synthesis in moderately malnourished patients. Ann Surg 1988; 208:143-149.
5. Ziegler TR, Young LS, Ferrari-Balioiera E, Demling RH, Wilmore DW. Use of human growth hormone combined with nutritional support in a critical care unit. J Parenter Enter Nutr 1990; 14:574-581.
6. Jiang SM, He GZ, Zhang SY, Wang X-R, Yang N-F, Zhu Y. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 1989; 210:513-524.
7. Ward HC, Halliday D, Sim AJW. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 1987; 206:56-61.
8. Mjaaland M, Unneberg K, Larsson J, Nilsson L, Revhaug A. Growth hormone after abdominal surgery attenuated forearm glutamine, alanine, 3-methylhistidine, and total amino acid efflux in patients receiving total parenteral nutrition. Ann Surg 1993; 217:413-422.
9. Hammarqvist F, Stromberg C, von der Decken A, Vinnars E, Wernerman J. Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole-body nitrogen economy after operation. Ann Surg 1992; 216:184-191.
10. Garibotto G, Barreca A, Russo R, Sofia A, Araghi P, Cesarone A, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patient. J Clin Invest 1997; 99:97-105. This study demonstrates the effect of a disease state on IGFBPs.
11. Wilmore DW, Moylan JA, Briston B, Malaspina M, Fiorini F, Minuto F, Tizianello A. Anabolic effects of human growth hormone and high caloric feedings following thermal injury. Surg Gynecol Obstet 1974; 138:875-884.
12. Manson MJCK, Wilmore DW. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feedings. Surgery 1986; 100:188-197.
13. Byrne TA, Morrissey TB, Gatzen C, Benfell K, Nattakom TV, Scheltinga MR, et al. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg 1993; 218:400-418.
14. Vara-Thorbeck R, Guerrero JA, Ruiz-Requena E, Garcia-Carriazo M. Can the use of growth hormone reduce the postoperative fatigue syndrome. World J Surg 1996; 20:81-86.
15. Pape GS, Friedman M, Underwood LE, Clemmons DR. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991; 99:1495-1500.
16. Burdet L, Demuralt B, Schultz Y, Pichard C, Fitting JW. Administration of growth hormone to underweight patient with chronic obstructive pulmonary disease. A prospective randomized controlled study. Am J Respir Crit Care Med 1997; 156:1800-1806.
17. Knox JP, Wilmore DW, Demling RH, Sarraf P, Santos AA. Use of growth hormone for postoperative respiratory failure. Am J Surg 1996; 171:576-580.
18. Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 1990; 212:424-429.
19. Schambelan M, Mulligan K, Grunfeld C, Darr ES, LaMarca A, Kotler DP, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996; 125:873-882.
20. Ross JM, Wilmore DW. Workshop report: endocrinology in catabolic illness. Endocrinol Metab 1996; 3:115-118.
21. Jauck KW. Growth hormone interventions in the postsurgical patients. Presented at International Workshop on Cellular and Molecular Mechanisms in Surgery and Critical Care, Bonn, Germany, 5 March 1993.
22. Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. Growth hormone-releasing hormone and growth hormone secretion in disease and aging. Recent Prog Horm Res 1997; 52:215-244.
23. Knox JB, Demling RH, Wilmore DW, et al. Hypercalcemia associated with the use of human growth hormone in an adult surgical intensive care unit. Arch Surg 1995; 130:442-445.
24. Ogilvy-Stuart AL. Safety of growth hormone after treatment of a childhood malignancy. Horm Res 1995; 44(Suppl. 3):73-79.
25. Clayton PE, Shalet SM, Gattameneni HR, Price DA. Does growth hormone cause relapse of brain tumors? Lancet 1987; i:711-713.
26. Pharmacia and Upjohn. Important Drug Warning 10-11 1997 USA.
27. Knox J, Demling R, Wilmore D, Sarraf P, Santos A. Increased survival after major thermal injury: the effect of growth hormone in adults. J Trauma 1995; 39:526-530.
28. Ramirez RJ, Wolf SE, Barrow RE, Hemdon DN. Growth hormone is safe and efficacious in the treatment of severe pediatric burns. Ann Surg 1998; 228:439-446. This study presents the strongest evidence to date for the use of GH in catabolic patients.
29. Wilmore DW, Lacey JM, Soultanakis RP, Bosch RL, Byrne TA. Factors which predict a successful outcome after pharmacologic bowel compensation. Ann Surg 1997; 226:288-293.
30. Dawson JM, Greathead HMR, Craigon J, Hachey DL, Reeds PJ, Pell JM, et al. The interaction between nutritional status and growth hormone in young cattle: differential responsiveness of fat and protein metabolism. Br J Nutr 1998; 79:275-286.
31. Ranke MB, Elmlinger M. Functional role of insulin-like growth factor binding proteins. Horm Res 4 (Suppl.):9-15.
32. Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study. J Clin Endocrinol Metab 1995; 80:2082-2087.
33. Geerling BJ, Badart, Smook A, Stockbrugger RW, Brumma RJM. Comprehensive nutritional status in patients with long-standing Crohn's disease currently in remission. J Clin Nutr 1998; 67:919-926. This paper should be read by all providers who care for patients with gastrointestinal disease.
34. Persinger R, Byrne TA, Browing B, Wilde A, Tu N, Wilmore DW. Evidence of essential fatty acid deficiency in patients receiving long-term parenteral nutrition despite use of fat emulsion. J Parenter Enter Nutr 1995; 19(Suppl.):205.
35. Jeppsen PB, Hoy CE, Mortensen PB. Essential fatty acid deficiency in patients receiving home parenteral nutrition. Am J Clin Nutr 1998; 68:126-133.
36. Hart MH, Grandjean CJ, Park JHY, et al. Essential fatty acid deficiency and postresectional mucosal adaptation in the rat. Gastroenterology 1988; 94:682-687.
37. Estivariz CF, Ziegler TR. Nutrition and the insulin-like growth factor system. Endocrinology 1997; 1:65-71.
38. Snyder DK, Gemmons DR, Underwood LE. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans. J Clin Endocrinol Metab 1989; 69:745-752.
39. Welbourne TC. Increased plasma bicarbonate and growth hormone after an oral glutamine load. Am J Clin Nutr 1995; 61:1058-1061.
40. Welbourne TC. Intraorgan glutamine flow in metabolic acidosis. Am J Physiol 1987; 253:F1069-1076.
41. Balteskard L, Unneberg K, Mjaaland M, Jenssen TGH, Revhaug A. Growth hormone and insulin-like growth factor I promotes intestinal uptake and hepatic release of glutamine in sepsis. Ann Surg 1998; 228:131-139.
42. Oguchi S, Walker WA, Sanderson IR. Differentiation and polarity alter the binding of IGF-1 to human intestinal epithelial (caco-2) cells. J Pediatr Gastroenterol Nutr 1995; 20:148-155.
43. Oguchi S, Walker WA, Sanderson IR. Profile of IGF-binding proteins secreted by intestinal epithelial cells changes with differentiation. Am J Physiol 1994; 267:G843-850.
44. Nishimura A, Fujimoto M, Oguchi S, Fusunyan RD, MacDermott RP, Sanderson IR. Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells. Am J Physiol 1998; 275:E55-63.
45. Tappenden KA, Drozdowski LA, Thomson ABR, McBurney Ml. Short-chain fatty acid-supplemented total parenteral nutrition alters intestinal structure, glucose transportation (GCUT 2) mRNA and protein, and proglucagon mRNA abundance in normal rats. J Clin Nutr 1998; 68:118-125. Both of the last two papers provide mechanisms for the function of short-chain fatty acids on the intestinal mucosa.